A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

NCT02737072 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: LY2510924
DRUG: Durvalumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]